RedHill Biopharma (RDHL) Long-Term Investments (2025)

RedHill Biopharma (RDHL) reported Long-Term Investments of $12.0 million for Q4 2025.

RedHill Biopharma (RDHL) Long-Term Investments (2025) Analysis & Trends

RedHill Biopharma (RDHL) has 1 years of Long-Term Investments data on file, last reported at $12.0 million in Q4 2025.

  • Long-Term Investments for Q4 2025 came in at $12.0 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $12.0 million (changed N/A YoY), and the FY2025 annual result was $12.0 million, changed N/A from the prior year.
  • Long-Term Investments steadied at $12.0 million in Q4 2025 per RDHL's latest filing.
  • Over five years, Long-Term Investments peaked at $12.0 million in Q4 2025 and troughed at $12.0 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Investments (Qtr)
1 Teva Pharmaceutical Industries 39.72 Bn 35.98 Bn 1.97 Bn -
2 Zoetis 34.61 Bn 32.67 Bn 1.62 Bn -
3 United Therapeutics 24.07 Bn 21.91 Bn 648.10 Mn 1.32 Bn
4 Aurora Cannabis 16.98 Bn 16.91 Bn 33.43 Mn -
5 Neurocrine Biosciences 16.64 Bn 15.32 Bn 800.70 Mn 1.33 Bn
6 Elanco Animal Health 12.19 Bn 11.76 Bn 785.00 Mn -
7 Alkermes 7.37 Bn 6.86 Bn -116.06 Mn 26.36 Mn
8 Hims & Hers Health 6.62 Bn 5.87 Bn 396.79 Mn -
9 Lantheus Holdings 6.47 Bn 5.97 Bn 230.92 Mn 1.90 Mn
10 RedHill Biopharma 119.32 Mn 119.32 Mn - 12.05 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 12.05 Mn